Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer

World Journal of Urology

Volumn 15, Issue 2, 1997, Pages 112-119

  Cordon Cardo, Carlos ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER TUMOR; CYTOGENETICS; GENETICS; HUMAN; IMMUNOLOGICAL PROCEDURES; METHODOLOGY; MOLECULAR BIOLOGY; ONCOGENE; PATHOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

CYTOGENETICS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOLOGIC TECHNIQUES; MOLECULAR BIOLOGY; ONCOGENES; PATHOLOGY; URINARY BLADDER NEOPLASMS;

EID: 0030626916     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02201982     Document Type: Article

References (72)

1. Altausen AK. Prout GR. Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J U ml 116: 575
2. Atkin NB. Baker MC (19X5) Cytogenetic study of ten carcinomas of the bladder: involvement of chromosomes 1 and 11. Cancer Genet Cytogenet 15: 253
3. Babu VR. Lutz MD. Miles BJ. Farah RN. Weiss L. Van DD (1987) Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopaihology. Cancer Res 47: 6800
4. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235-248
5. Cairns P. Proctor AJ. Knowles MA (1991) Loss of hctcrozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6: 2305
6. Cairns P. Shaw ME. Knowles MA (1993) Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 53: 12 30
7. Cairns P. Polascik TJ. Eby Y. et al (1995) Frequency of homozygous deletion at p!6'CdKN2 in primary human tumours. Nature Genet 11:210
8. Cordon-Cardo C (1995) Mutation of cell cycle regulators: biological and clinical implications for human neoplasias. Am .1 Pathol 145: 545
9. Cordon-Cardo C. Wartinger D. Petrylak D. et al (1992) Altered expression of the retinoblastoma gene product is a prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251
10. Cordon-Cardo C. Dalbagni D. Sarkis A. Reuter VE (1994). Genetic alterations associated with bladder cancer. In: DeVita VT. Hellman S. Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp. 71 -83
11. Cordon-Cardo C. Dalbagni D. Saez GT. cl al (1994) TP53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347
12. Czerniak B. Deitch D. Simmons H. Elkind P. Herz F. Koss LG (1990) Ha-ras gene codon 12 mutations and DNA ploidy in urinary bladder carcinomas. Br J Cancer 62: 762
13. Czerniak B. Cohen GL. Elkind P. et al (1992) Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol 23: 1199
14. Dalbagni G. Presti J. Reuter V. Fair WR. Cordon-Cardo C (1993) Genetic alterations in bladder cancer. Lancet 324: 469
15. Dalbagni G. Presti JC. Reuter VE. et al (1993) Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2: 4
16. Esrig D. Elmajian D. Groshen S. et al ( 1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Enel 1 Med 331: 1259
17. Fearon ER. Feinberg AP. Hamilton SH, Vogelstein B (1985) Loss of genes on the short arm of chromosome 1 1 in bladder cancer. Nature 318: 377
18. Fitzgerald JM, Ramchurren N, Rieger K. et al (1995) Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 87: 129
19. Fujimoto K, Yamada Y, Okajima E. et al (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393
20. Fujifa K, Srivastava SK. Kraus MH (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sei USA 82: 3849
21. Gibas Z. Prout GR. Connolly JG, Pontes JE. Sandberg AA (1984) Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 44: 1257
22. Gruis NA, Weaver-Feldhaus J, Liu Q (1995) Genetic evidence in melanoma and bladder cancers that pi6 and p53 function in separate pathways of tumor suppression. Am J Pathol 146: 1199
23. Habuchi T, Ogawa O. Kakehi Y. et al (1993) Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 53: 579
24. Hannon GJ, Beach D (1994) p!51NK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371: 257
25. Hopman AHN, Moesker O. Smeets W, Pauwels RPE. Vooijs GP, Ramaekers FCS (1991) Numerical chromosome 1. 7. 9. and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 51: 644
26. Ishikawa J, Xu H-J, Hu S-X. et al (1991) [motivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51: 5736
27. Kamb A, Liu Q, Harshman K. Tavtigian S, Cordon-Cardo .C. Skolnick MH (1994) Rates of p!6 (MTS1) mutations in primary tumors with 9p loss. Science 265: 416
28. Kamb A, Gruis NA, Weaver-Feldhaus J, et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436
29. Koss LG (1975) Atlas of tumor pathology: tumors of the urinary bladder (fasicle 11), 2nd edn. Armed Forces Institute of Pathology, Washington, D.C.
30. Koss L (1992) Diagnostic cytology and its histopathologic bases. 4th edn. Lippincott, Philadelphia
31. Levine AJ (1993) The tumor suppressor genes. Annu Rev Biochem62: 623-651
32. Lianes P, Orlow I. Zhang ZZ. et al (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86: 1325
33. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53: 365
34. Logothetis CJ, Xu H-J, Ro JY, et al (1992) Altered retinoblastoma protein expression and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1257
35. Marshall CJ (1991) Tumor suppressor genes. Cell 64: 313-326
36. Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinomas. Cancer Res 50: 2530
37. Miyao N, Tsai YC, Lerner SP, et al (1993) Role of chromosome 9 in human bladder cancer. Cancer Res 53: 4066
38. Momand J. Zambetti G, Oison D. et al (1992) The mdm-2 oncogene product forms a complex with the p-53 protein and inhibits TP53-mediated transactivation. Cell 69: 1237
39. Neal DE, Marsh C, Bennet MK, Hall RR, Harris AL (1985) Epidermal growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumors, lancet I: 366
40. Neal DE, Sharpies L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619
41. Nguyen PL. Swanson PE. .las/cv W. et al (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: multivariiite survival analysis. Am .1 Clin Palhol 101: 166
42. Oliiier JD. Kinzler KW, Metlzer PS. et al (1992) Amplification ol a gene encoding a p53 associated protein in human sarcomas. Nature 358: 80
43. Olumi AK Tsai YC. Nichols Pw. et al (1990) Alloue loss of chromosomes I7p distinguishes high grade from low grade transitional cell carcinoma of the bladder. Cancer Res 50: 70X1
44. Ooi A. Her/ F. Setsuko I. et al (1994) Ha-ras codon 12 mutation in papillary tumors of the urinary bladder. A retrospective study. I n l J Oncol 4: 85
45. Orlow I. Lianes P, Lacombe L. Dalbagni G. Reuter VE. CordonCardo C (1994) Chromosome 9 deletions and microsalellite alterations in human bladder tumors. Cancer Res 54: 2848
46. Orlow 1. Lacombe L. Hannon GJ, et al (1995) Deletion of the p!6 and pi5 genes in human bladder tumors. J Nail Cancer Inst 87: 1524
47. Parsons .IT, Parsons S.I (1993) Prolein-lyrosine kinases, oncogenes, and cancer. In: DeVita VT. Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott. Philadelphia, pp 3 -17
48. Presti JC. Reuter VE. Galan T. Fair WR. Cordon-Cardo C (1991) Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51: 5405
49. Prout GR (1977) Bladder carcinoma and a TNM system of classification. J Urol 117: 583
50. Rao JY. Hemstreet GP. Hurst RE. el al (1993) Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sei USA 90: 8287
51. Reddy EP, Reynolds RK. Santos E, Barbacid M (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 bladder carcinoma oncogene. Nature 300: 149
52. Reuter VE, Melamed MR (1989) The lower urinary tract. In: Sternberg SS (ed) Diagnostic surgical pathology. Raven. New York, p 1355
53. Rupperl JM. Tokino K, Sidransky D (1994) Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53: 5093
54. Sarkis AS, Zhang Z-F. Cordon-Cardo C. et al (1993) p53 nuclear overe.xpression and disease progression in Ta bladder carcinoma. Int J Oncol 3: 355
55. Sarkis AS. Dalbagni G. Cordon-Cardo C. et al (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Nail Cancer Inst 85: 53
56. Sarkis AS. Dalbagni G, Cordon-Cardo C. el al (1994) Associalion of p53 nuclear overexpression and lumor progression in carcinoma in silu of ihe bladder. J Urol 152: 388
57. Sarkis AS. Bajorin DF. Reuter VE, et al (1995) The prognostic value of p53 nuclear overexpression in palienles with invasive bladder cancer treated with neoadjuvant M-VAC. J Clin Oncol 13: 1384
58. Sato K. Moriyama M. Moris S. el al (1992) An immunohislologic evalualion of c-erbB-2 gene producl in palienls with urinary bladder carcinoma. Cancer 70: 2493
59. Sauter G. Moch H. Moore D. el al (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53: 2199
60. Sauler G, Deng G, Moch H. el al (1994) Physical deletion of ihe p53 gene in bladder cancer. Am J Pathol 144: 756
61. Serrano M. Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D CDK4. Nalure 366: 704
62. Sidransky D, Von Eschenbach A, Tsai YC, el al (1991) Idenlificalion of p53 gene mulalions in bladder cancers and urine samples. Science 252: 706.
63. Smeels W, Pauwels R, Laarakkers L, Debruyne F, Geraedts J (1987) Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet Cytogenel 29: 29
64. Spruck CH. Ohneseit PE. Gonzalez-Zulueta M, et al (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784
65. Spruck CH. Gonzalez-Zulueta M, Shibata A, et al (1994) p!6 gene in uncultured tumours. Nature 370: 183
66. tsai YC. Nichols Pw. Hiti AL. Williams Z. Skinner DG, Jones PA (1990) Allelic losses of chromosomes 9. 11, and 17 in human bladder cancer. Cancer Res 50: 44
67. Underwood M, Barleu J. Reeves J. Gardiner DS, Scott R, C'ookc T (1995) C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? C'ancer Res 55: 2422
68. Vanni R. Scarpa RM. Nieddu M. Usai E (1988) Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet 30: 55
69. Visvanathan KV. Pocock RD. Summerhayes 1C (1988) Preferential and novel activation of Ha-ras in human bladder carcinoma. Oncogene Res 3: 77
70. Waldman FM. Carroll PR, Kerschmann R. Cohen MB, Field FG, Mayall BH (1991) Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 51: 3807
71. Williamson M, Elder PA. Shaw ME. Devlin J. Knowles M (1995) p!6(CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569
72. Wood D. Wartinger DD. Reuter V. Cordon-Cardo C. Fair WR. Chaganti RS (1991) DNA. RNA and immunohistochemical characterization of the HER-2,neu oncogene in transitional cell carcinoma of the bladder. J Urol 146: 1398